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The amino acid sequence of a segment of 106 residues of C4d has been determined by automated sequence 
analysis of fragments obtained by CNBr cleavage and enzymic digestion with trypsin. Polymorphism has 
been detected at 3 positions. Residues 9 and 12 are either valine and leucine or alanine and arginine, 
respectively. Residue 102 is either valine or arginine. When comparing the protein sequence with the 
nucleic, acid sequence [Carroll, M. and Porter, R.R. (1983) Proc. Natl. Acad. Sci. USA 80, in press] 
alanine or serine are found at position 98. These results may in part help to explain the inherited variants 
of human C4 seen on gel electrophoresis. 
Human C4d Sequence Polymorphism 
1. INTRODUCTION 
In man, complement component C4 is a highly 
pol~orphic glycoprotein with a M of about 
200 000 [Z]. It consists of 3 polypeptide chains 
linked by disulphide bonds, the (Y-, ,i?- and y- 
chains, with M-values of about 93 000,75 000 and 
33 000, respectively [3,4]. The inherited variability 
of C4 has been studied by electrophoresis on 
agarose gels followed by immunofixation [5,6]. 
The various haplotypes seen, have been grouped 
under fast moving and slow moving components 
now called A and B. Population genetic studies 
have suggested that the two loci are closely linked 
to each other and are located between the HLA-B 
and HLA-D loci on human chromosome 6 171. 
Two-dimensional gel electrophoresis has shown 
that the electrophoretic polymorphism in C4 is due 
to a charge difference in the m-chain [8]. These dif- 
ferences are also reflected in the C4d fragment 
which comes from the central portion of the a- 
chain [13]. 
Red blood cell antigens Chido and Rogers, 
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which are known to be related to the C4 molecule 
151 have been shown to be carried on the C4d frag- 
ment of the a-chain [9,10]. C4A and C4B 
molecules react, respectively, with anti-Rogers and 
anti-Chid0 sera. More recently, it has been 
demonstrated [I l] that polymorphism in the LY- 
chain of C4 is not only related to charge, but is also 
due to a difference in M,. The a-chain of C4A has 
a Mr of 96 000 and is anti-Rg positive while the cy- 
chain of C4B has a M, of 93 000 and is anti-Ch 
positive. 
Here we present evidence that polymorphism in 
C4 is in part due to differences in the amino acid 
sequence of fragment C4d. 
2. MATERIALS AND METHODS 
2.1. Isolation of C4 and the fragment C4d 
Human C4 was prepared by sequential 
chromatography of the pseudo-globulin fraction 
of pooled human serum through DEAE-Sephadex 
A-50, DEAE-Sepharose CL-6B and Sephacryl 
S-200 (superfine grade) as in 14,121. The prepara- 
tion of C4b from C4, and of C4d from C4b was 
carried out as in [13], with the exception that fac- 
tor I was prepared from human plasma by 
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monoclonal-antibody affinity chromatography 
H41. 
2.2. ~rif~~~tio~ of CNBr and tryptic fr~~menfs 
of C4d 
CNBr fragments of C4d were prepared by in- 
cubating the reduced and alkylated protein with 
CNBr in 70% (v/v) formic acid in the dark for 
24 h at 4% The CNBr peptides were purified 
from the digest by gel filtration on Sephadex G-50 
(superfine) as described in 1151. 
Further purification of the peptides was achiev- 
ed by high pressure liquid chromatography 
(HPLC) using ap-Bondapak cl8 column and one 
of two different solvent systems as in 1161. In 
system A, 0.1% tri~uoroacetic acid and a solvent 
mixture of acetonitrile-methanol-propan-2-01 
(1: 1: 1, by vol.) was used, and in system B 0.1% 
NHdHC03 and acetonitrile. 
Trypsin digestions of reduced, alkylated and 
succinylated C4d, and of CNBr peptide CN-3 were 
carried out using conditions previously reported 
[14]. The succinylated tryptic peptides were 
purified by gel filtration on Sephadex G-50 (super- 
fine) and HPLC using system B. In one instance 
(peptide ST3/F/DE-C) ion-exchange chromato- 
graphy using a column of DEAE-Sephacel as 
described in f16J was also performed. The trypsin 
digest of peptide CN-3 
HPLC using system B. 
1 10 
was directly separated by 
2.3. Amino acid analysis and sequence deter- 
mination 
Amino acid analysis was carried out as in [12]. 
Automated amino acid sequence determination 
was performed on a Beckman 890~ sequencer as 
described in [I6]. The phenylthiohydantoin 
derivatives were identified and quantitated by 
HPLC [lci]. 
3. RESULTS AND DISCUSSION 
Previous work has established the amino acid se- 
quence of 90 residues at the N-terminus of C4d 
1151. Polymorphism was not detected in that se- 
quence. The sequence of another 106 residues from 
within the C4d fragment has now been determined 
by automated sequence analysis of fragments ob- 
tained by CNBr cleavage and enzymic digestion 
with trypsin. This segment contains a number of 
polymorphic positions and represents the first 
evidence at the protein sequence level of the well- 
established polymorphism of C4. 
CNBr digestion of C4d followed by gel filtration 
on Sephadex G-50 produced 5 major pools (see fig. 
2 in 1151). Subsequent analysis of pool D by HPLC 
using system B gave 3 major fragments, CN-5, 
CN-6a and CN-6b. CN-5 was previously sequenced 
and shown to belong to the N-terminal region of 
C4d [ 151. Cn-6a and CN-6b, 34 and 27 amino acids 
long, respectively, were subjected to automated se- 
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Fig. 1 I Automated sequence analysis and alignment of CNBr peptides CN-3, CN-6a and CN-6b, and the succinylated 
tryptic peptides ST3/F/DE-C, ST5/B22 and ST4/e of C4d. Details of the automated Edman degradation and 
identification of the PTH derivatives are given in [16]. (+) denotes that positive identification of a particular residue 
was made. Amino acid residues differing between the peptides are boxed in. 
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quence analysis. Thirty residues of CN-6a and 11 
residues of CN-6b were determined (fig. 1). A third 
CNBr peptide CN-3 was purified from pool A by 
HPLC using system A. CN-3, assigned as the C- 
terminal peptide due to the lack of Hse, is compos- 
ed of about 65 residues; 23 residues were identified 
by sequence analysis (fig. 1). 
The alignment of the 3 CNBr peptides and the 
extension of the sequence was made possible by the 
isolation of two peptides, ST4/e and ST3/F/DE- 
C, after trypsin cleavage of succinylated C4d. Pep- 
tide ST4fe contains 43 amino acid residues. The 
first 36 residues were determined and were found 
to overlap CN-6a, CN-6b and CN-3, aligning them 
in that order (fig. 1). The second peptide, 
ST3/F/DE-C was analysed for 28 cycles and gave 
an overlap of 6 residues with CN-Ga, providing an 
N-terminal extension to the 3 contiguous CNBr 
fragments (fig. 1). 
In total this segment represents a continuous se- 
quence of 106 residues. The cDNA sequence 
corresponding to this region of C4d has been deter- 
mined [l]. Both sequences are identical, with the 
exception of position 88. The cDNA codes for a 
Ser at this position, whereas Ala was determined 
by amino acid sequence analysis. This discrepancy 
is likely to be due to the polymorphism of C4. 
A better documented instance of polymorphism 
was obtained from another succinylated tryptic 
peptide, STS/B22. This peptide of 12 residues was 
sequenced in its entirety (fig. 1). It is homologous 
to the N-terminal sequence of the segment except 
for positions 9 and 12 where Ala and Arg were 
found in contrast to the Val and Leu residues, 
respectively, found in ST3/F/DE-C. Comparison 
of the amino acid sequence with that derived from 
the cDNA sequence 111 suggests that the tryptic 
peptides ST3/F/DE-C and STS/B22 are derived 
from a chymotrypsin-like cleavage at the carboxyl 
side of a Tyr residue prior to Ala at position 1. 
Another polymorphic location in this 106- 
residue segment of C4d occurs at residue 102. At 
this position a Val residue was determined by se- 
quence analysis of CN-3 (fig. 1). Sequence analysis 
of a pool from a HPLC separation of a tryptic 
digest of CN-3 gave an unambiguous although 
double sequence, related to the N-terminus of 
CN-3, namely Ala-Asp-Gln-Ala-Ala-Ala-Trp-Leu- 
Thr-Arg (positions 84 to 93) and Gln-Gly-Ser-Phe- 
Gln-Gly-Gly-Phe-Thr-Arg (positions 94 to 102). 
This result indicated that both Val and Arg could 
be found at position 102 (fig. 1). A tryptic peptide 
starting with the sequence Ser-Thr-Gln-Asp con- 
firmed this. 
In summary, polymorphism at 4 positions 
within this 106 residue segment of C4d have been 
detected, These are Val/Ala at position 9, 
Leu/Arg at position 12, SerfAla at position 88 and 
finally Val/Arg at position 102. As suggested from 
the cDNA sequence, Val-9, Leu-12 and Ser-88 are 
associated with one form of C&i. This is consistent 
with peptide ST3/F/DE-C containing Val-9 and 
Leu-12. At present it is not possible to decide 
whether the Val-9, Leu-12, Ser-88 form of C4d has 
either Val or Arg at position 102. 
Since the amino acid sequence described is that 
of a protein isolated from pooled serum, it cannot 
be related directly to a specific form of C4. Recent- 
ly, fragments resembling C4d (Tyr-C4d) have been 
isolated from trypsin-digested C4 [17]. The major 
fragments of Mr 30 000 and 28 000 were found to 
carry the Rogers and Chido determinants, respec- 
tively. Sequence analysis showed that the dif- 
ference was at the C-terminus of the fragments. It 
is possible that the Leu/Arg polymorphism at posi- 
tion 12 of this study contributed to the different 
sizes of these Tyr-C4d fragments and suggests that 
the Val-9, Leu-12, Ser-88 form of C4d might be 
associated with the larger Rogers (C4A) variant, 
and conversely the Ala-g, Arg-12, Ala-88 form 
with the smaller Chido (C4B) variant. Further 
work at the genomic level will undoubtedly provide 
the answer. 
ACKNOWLEDGEMENTS 
We wish to thank Professor R.R. Porter for his 
continued advice and encouragement during the 
course of this work. We thank Mr T. Gascoyne for 
performing the amino acid analysis, Mr A. Willis 
for sequence analysis and Miss N. Janjua for ex- 
cellent technical assistance. D.N.C. held a State 
Scholarship from the Government of West Bengal, 
India. 
389 
Volume 154, number 2 FEBS LETTERS April 1983 
REFERENCES 
[I] Carroll, M. and Porter, R.R. (1983) Proc. Natl. 
Acad. Sci. USA, in press. 
[2] Rosenfeld, S.I., Ruddy, S. and Austen, K.F. (1969) 
J. Clin. invest. 48, 2283-2292. 
[3] Schrieber, R.D. and Mtiiller-Eberhasd, H.3. (1974) 
J. Exp. Med. 140, 1324-1335. 
[4] Gigli, I., von Zabern, I. and Poster, R.R. (1977) 
Biochem. J. 165, 439-446. 
[5] O’Neill, G.J., Yang, S.Y., Tegoli, J., Berger, R. 
and DuPont, B. (1978) Nature 273, 668-670. 
[6] Awdeh, Z.L. and Alper, C.A. (1980) Proc. Natl. 
Acad. Sci. USA 77, 8576-8580. 
[7] Weitkamp, L.R. and Lamm, L.U. (1982) 
Cytogenet. Cell Genet. 32, 130-143. 
[8] Mevag, B., Olaisen, B. and Teisberg, P. (1981) 
Stand. J. immunot. 14, 303-307. 
[9] Tilley, C.A., Romans, D.G. and Crookston, M.C. 
(1978) Nature 276, 713-715. 
[lo] Chu, V.F.H., Marsh, W.L. and Gigli, I. (1982) J. 
Immunol. 128, 181-185. 
[l l] Roos, M.H., Mollenhauer, E., Demant, P. and 
Rittner, C. (1982) Nature 298, 854-856. 
[12] Campbell, RD., Dodds, A.W. and Porter, R.R. 
(1980) Biochem. J. 189, 67-80. 
1131 Press, E.M. and Gagnon, J. (1981) Biochem. J. 
199, 3.51-357. 
[14] Hsiung, L.-M., Barclay, A.N., Brandon, M.R., 
Sim, E. and Porter, R.R. (1982) Biochem. J. 203, 
293-298. 
[15] Campbell, R.D., Gagnon, J. and Porter, R.R. 
(1981) Biochem. J. 199, 359-370. 
1161 Christie, D. and Gagnon, J. (1982) Biochem. J. 
201, 555-567. 
1171 Lundwall, A., Hellman, U., Eggertsen, G. and 
Sjaquist, J. (1982) Molec. Immunol. 19, 
1655-1665. 
390 
